Analyst Research

Report Title Price
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC Starts Mid-Stage Tuberculosis Drug Trial in Africa-Reuters


Tuesday, 11 Dec 2012 06:00am EST 

Reuters reported that AstraZeneca PLC, which developed the medicine known as AZD5847, is working with the United States National Institute of Allergy and Infectious Diseases and Case Western Reserve University School of Medicine on the Phase IIa clinical study of that new experimental drug that may fight drug-resistant strains of the lung disease tuberculosis. The drug is being tested in South Africa, where the first patient has been enrolled into a mid-stage clinical trial. 

Company Quote

3781.5
23.0 +0.61%
17 Apr 2014